Par Pharma (PRX) +6.5% after a Delaware court rules five patents covering Santarus' (SNTS...

|About: Par Pharmaceutical Comp... (PRX)|By:, SA News Editor

Par Pharma (PRX) +6.5% after a Delaware court rules five patents covering Santarus' (SNTS -31.9%) stomach drug Zegerid are invalid due to "obviousness." Analysts say Par Pharma's proposed generic is Zegerid's only challenger, and while it hasn't received FDA approval, the ruling removes a large hurdle.